Consensus iCAD, Inc.

Equities

ICAD

US44934S2068

Real-time Estimate Cboe BZX Other stock markets 01:39:35 2024-04-26 pm EDT			5-day change	1st Jan Change
1.475 ^USD	-0.34%		-4.55%	-16.95%

Apr. 11	ICAD, Inc. Showcases New Profound Cloud, Enhanced Profound Detection Workstation Features at SBI Annual Symposium	CI
Apr. 09	ICAD, Inc. and Densitas, Inc. Partner to Enhance Precision Breast Health with Leading AI Solutions for Mammography Quality, Cancer Detection, and Risk Evaluation	CI

Evolution of the average Target Price on iCAD, Inc.

Price target over the last 5 years

History of analyst recommendation changes

3efcecc7f7682.zEjWWtSvhHXzuXVHTcG_bpWEeWypLbqaM6DrWx01OU4.tTCFApuY1SrGgB92fIXsVsfFPx_QedHQHs2CIkV8UAKfOa8egZ3TFKbaJA~88fb38a4637652747f6580fd99380bf3

Analyst Recommendations on iCAD, Inc.

Lake Street Adjusts Price Target on icad to $5 From $2.50, Maintains Buy Rating	23-07-19	MT
JMP Securities Adjusts iCAD's Price Target to $4 From $7, Keeps Outperform Rating	23-04-13	MT
Oppenheimer Adjusts iCAD Price Target to $4 From $5, Maintains Outperform Rating	23-04-04	MT
JMP Securities Adjusts icad's Price Target to $7 From $13, Maintains Market Outperform Rating	22-09-01	MT
Lake Street Adjusts icad Price Target to $8 From $13, Maintains Buy Rating	22-08-11	MT
BTIG Adjusts icad's Price Target to $8 from $10, Keeps Buy Rating	22-06-24	MT
Guggenheim Downgrades ICAD to Neutral From Buy	22-01-18	MT
Oppenheimer Adjusts icad PT to $16 From $22, Maintains Outperform Rating	22-01-05	MT
Oppenheimer Adjusts icad PT to $22 From $24, Maintains Outperform Rating	21-11-10	MT
JMP Securities Adjusts Price Target on icad to $18 From $22, Maintains Market Outperform Rating	21-11-10	MT
ICAD : B. Riley Lowers icad's PT to $19 from $23 After Q2 Results Miss Estimates, Keeps Buy Rating	21-08-10	MT
ICAD : Oppenheimer Adjusts iCAD PT to $24 From $28, Maintains Outperform Rating	21-08-06	MT
ICAD : Guggenheim Initiates icad at Buy Rating With $24 Price Target	21-04-22	MT
ICAD, Inc. Announces New Research Indicates ProFound AI May Reduce Interval Breast Cancer Rates	21-03-31	CI
ICAD : BTIG Starts ICAD at Buy With $25 Price Target	21-03-23	MT
ICAD : Oppenheimer Adjusts iCAD PT to $28 From $27, Maintains Outperform Rating	21-03-16	MT
ICAD : B. Riley Raises ICAD's Price Target to $23 From $18, Keeps Buy Rating	21-02-26	MT
ICAD : Oppenheimer Starts ICAD at Outperform With $27 Price Target	21-02-26	MT
ICAD : Cantor Fitzgerald Starts Icad at Overweight With $19 Price Target	21-01-29	MT
ICAD : B. Riley Adjusts Icad's Price Target to $18 From $15, Maintains Buy Rating	20-12-15	MT
ICAD : B. Riley Starts Icad at Buy With $15 Price Target	20-12-03	MT